仟源医药公告，股东翁占国减持计划已于2026年2月12日届满，期间通过集中竞价于2025年11月13日至 11月26日减持153.53万股，占总股本0.60%，均价10.98元/股；通过大宗交易于11月19日至11月25日减持 496.71万股，占1.94%，均价8.5元/股；累计减持650.24万股，占2.54%。减持后持股降至927万股、 3.62%，减持计划实施完毕。 ...

证券代码：300254 证券简称：仟源医药 公告编号：2026-022 山西仟源医药集团股份有限公司 关于持股5%以上股东减持股份实施情况暨减持完毕的公告 公司股东翁占国保证向本公司提供的信息内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 山西仟源医药集团股份有限公司（以下简称"公司"）于 2025 年 10 月 22 日披露了《关于持股 5%以上股东减持股份的预披露公告》（公告编号：2025-068）。 公司持股 5%以上股东翁占国先生计划通过集中竞价交易方式及大宗交易方式合 计减持公司股份不超过 7,683,100 股（占公司总股本比例不超过 3%）。其中，以 集中竞价交易方式减持的，在任意连续 90 个自然日内减持股份的总数不超过公 司总股本的 1%；以大宗交易方式减持的，在任意连续 90 个自然日内减持股份的 总数不超过公司总股本的 2%（减持期间为 2025 年 11 月 13 日至 2026 年 2 月 12 日）。具体内容详见公司于 2025 年 11 月 19 日、2025 年 11 月 24 日分别在巨潮 资讯 ...

财报分析 经济观察网2026年2月10日晚间，仟源医药（300254）发布公告称，公司第一大股东赵群所持1578万股 股份被司法冻结，占其持股的100%及公司总股本的6.16%，冻结金额为5000万元，系因个人诉讼的诉前 保全。公司强调该事项与经营无关，不会对日常运营产生重大影响。此事件为近期核心热点，可能引发 市场对股权稳定性的关注。 股票近期走势 近7天(截至2026年2月13日)，仟源医药股价呈现波动：2月10日受事件影响收盘报12.00元(单日涨 3.00%)，2月11日大幅回调至11.44元(跌4.67%)，2月13日反弹至11.82元(涨3.96%)。区间振幅达7.64%， 换手率活跃，显示短期情绪分化。技术面显示股价临近20日压力位11.9元，MACD指标偏强，但需注意 流动性风险。 机构观点 机构舆情中性，近期无新增评级变动。根据预测，2025年净利润同比预增115.69%，2026年预增 48.35%，反映长期盈利改善预期，但当前机构调研频率较低，市场关注度一般。 以上内容基于公开资料整理，不构成投资建议。 业绩方面，2025年第三季度公司营收2.38亿元(同比增14.82%)，归母净利润2 ...

Core Viewpoint - The AI medical sector experienced a decline of 0.66% on February 11, with QianYuan Pharmaceutical leading the drop. The Shanghai Composite Index rose by 0.09%, while the Shenzhen Component Index fell by 0.35% [1]. Group 1: Market Performance - The closing price of QianYuan Pharmaceutical was 11.44, down by 4.67%, with a trading volume of 209,800 shares and a transaction value of 243 million [2]. - The AI medical sector saw a net outflow of 1.345 billion from major funds, while retail investors contributed a net inflow of 1.14 billion [2][3]. Group 2: Individual Stock Performance - YoukeDe (688158) closed at 37.54, up by 5.12%, with a trading volume of 631,000 shares and a transaction value of 2.36 billion [1]. - AidiTe (301580) closed at 55.18, up by 4.63%, with a trading volume of 46,100 shares and a transaction value of 251 million [1]. - SanNuo Biology (300298) closed at 18.54, up by 2.71%, with a trading volume of 105,200 shares and a transaction value of 194 million [1]. - The top decliners included QianYuan Pharmaceutical (300254) and KaiPu Biology (300639), with declines of 4.67% and 4.23%, respectively [2].

Core Viewpoint - The precision medicine sector experienced a slight decline of 0.05% on February 11, with Qianyuan Pharmaceutical leading the drop [1] Market Performance - The Shanghai Composite Index closed at 4131.98, up by 0.09% - The Shenzhen Component Index closed at 14160.93, down by 0.35% [1] Fund Flow Analysis - The precision medicine sector saw a net outflow of 277 million yuan from main funds - Retail investors contributed a net inflow of 202 million yuan - Speculative funds recorded a net inflow of 74.36 million yuan [1]

近日，仟源医药（300254）发布公告称，公司第一大股东赵群所持1578万股被河北省石家庄市新华区人 民法院司法冻结，占其所持股份的100%及公司总股本的6.16%。 （仟源医药公告） 根据民事裁定书，赵群所持公司股份被司法冻结系因曹希同向石家庄新华区人民法院提起的诉前保全， 法院裁定的冻结金额为5000万元。 ...

Core Viewpoint - The major shareholder of Qianyuan Pharmaceutical, Zhao Qun, has had 15.78 million shares frozen by the court, representing 100% of his holdings and 6.16% of the company's total shares, due to a pre-litigation preservation request [1][2]. Group 1: Shareholder and Legal Issues - Zhao Qun's shares were frozen due to a court ruling related to a claim made by Cao Xitong, with the frozen amount set at 50 million yuan [1]. - The company clarified that the legal issues involving Zhao Qun are unrelated to the company and do not stem from any overdue debts or violations that could harm the company's interests [2]. Group 2: Company Performance - Qianyuan Pharmaceutical reported a significant decline in net profit for the first half of 2025, with a notable increase in revenue in the third quarter, achieving 238 million yuan, a 14.82% year-on-year growth, and a net profit of approximately 21.95 million yuan, up 106.06% [3]. - Despite the strong quarterly performance, the cumulative results for the first three quarters of 2025 showed a slight revenue increase of 0.44% to 611 million yuan, but a significant drop in net profit by 49.43% to about 22.33 million yuan [3][4]. - Financial expenses have increased by 50.80% year-on-year, reaching approximately 17.52 million yuan, primarily due to rising bank loan interest [4]. Group 3: Market Information - As of February 10, Qianyuan Pharmaceutical's stock closed at 12.00 yuan per share, with a total market capitalization of approximately 3.073 billion yuan [5].

仟源医药公告，持股5%以上第一大股东赵群所持公司股份800万股被司法冻结，占其所持股份比例 50.69%，占公司总股本比例3.12%；另有760.18万股被冻结，占其所持股份比例48.17%，占公司总股本 比例2.97%；18万股权激励限售股被冻结，占其所持股份比例1.14%，占公司总股本比例1.14%。 ...

山西仟源医药集团股份有限公司 关于持股5%以上第一大股东股份被司法冻结的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 山西仟源医药集团股份有限公司（以下简称"公司"）通过中国证券登记结 算有限责任公司系统查询获悉，持股 5%以上第一大股东赵群先生所持有的公司 股份被司法冻结，现将具体情况公告如下： 证券代码：300254 证券简称：仟源医药 公告编号：2026-021 2、赵群先生所涉上述诉讼与公司没有任何关联,亦不属于其大额债务逾期等违 约行为。 3、赵群先生不存在非经营性资金占用、违规担保等侵害上市公司利益的情形。 公司与赵群先生在资产、财务等方面均保持独立，本次股份冻结事项不会对公司治 股 东 名 称 是否为 控股股 东或第 一大股 东及其 一致行 动人 本次冻结数 量（股） 占其所 持股份 比例 占公司 总股本 比例 是否 为限 售股 冻结起始日 冻结到期日 冻结法 院 原因 赵 群 第一大 股东 8,000,000 50.69% 3.12% 否 2026-02-06 2029-02-05 河北省 石家庄 市新华 区人民 法院 司法 冻结 7, ...

Market Performance - The A-share market saw a collective increase in the three major indices, with the Shanghai Composite Index rising by 1.41%, the Shenzhen Component Index by 2.17%, and the ChiNext Index by 2.98% [1] - The North China 50 Index increased by 1.36% [1] - The total trading volume in the Shanghai and Shenzhen markets was approximately 22,494.73 billion yuan, an increase of about 1,037.54 billion yuan compared to the previous trading day [1] Shanxi Sector Analysis - The Shanxi sector performed steadily, with an overall increase of 0.61% and a trading volume of 120.25 billion yuan, indicating a positive market sentiment [1] - Among the 41 stocks in the Shanxi sector, 28 stocks rose, 12 fell, and 1 remained flat [1] Individual Stock Performance - Notable gainers included Jinlihua Electric and Huaxiang Co., both rising over 3%, while Dongjie Intelligent, Luhua Technology, and Huayang New Materials increased by over 2% [1] - Other stocks such as Beifang Copper Industry, Kexin Development, and Shitou Co. saw increases of over 1% [1] - Decliners included Jinkong Power and Lanyan Holdings, both dropping over 2%, while Shanxi Coking Coal and Qianyuan Pharmaceutical fell by more than 1% [1] - Several stocks, including Jinkong Coal Industry, Lu'an Environmental Energy, and Jinbo Biological, experienced milder declines, with losses contained within 1% [1]